|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||313.26 - 316.67|
|52-week range||313.26 - 316.67|
|Beta (5Y monthly)||0.43|
|PE ratio (TTM)||0.33|
|Earnings date||24 Jan 2023 - 30 Jan 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Cathie Wood remains optimistic. Her ARK Invest exchange-traded funds (ETFs) have continued to scoop up stocks during the steep downturn this year. But she's apparently not optimistic about all of her ARK holdings.
The FDA decides not to hold an advisory committee meeting for BioMarin Pharmaceuticals' (BMRN) regulatory filing seeking approval for hemophilia A gene therapy, valrox.
GSK, at the request of the FDA, is set to withdraw the U.S. marketing authorization for Blenrep. The FDA's request comes after the failure of a phase III confirmatory study, DREAMM-3.